Pfizer yesterday asked the Food and Drug Administration to expand the emergency use authorization for its COVID-19 vaccine booster to include youth aged 16 and 17. 

“It is our hope to provide strong protection for as many people as possible, particularly in light of the new variant,” tweeted Pfizer CEO Albert Bourla. 

FDA last month authorized, and the Centers for Disease Control and Prevention recommends (https://www.cdc.gov/media/releases/2021/s1119-booster-shots.html), a single booster dose of the Pfizer or Moderna COVID-19 vaccine for all individuals aged 18 or older at least six months after receiving the initial two-dose series or two months after receiving the single-dose Johnson & Johnson vaccine. 
 

Related News Articles

Headline
Hospital leaders from the AHA’s vaccine confidence initiative share tips for building COVID-19 vaccine confidence. “Getting more Americans vaccinated against…
Blog
This is a confusing time in the public health emergency. Americans are thinking less about COVID-19 on a daily basis and many are eager to move on. But COVID-…
Chairperson's File
Remaining resilient as new variants of COVID-19 spread. Launching mobile health services to help ensure equitable distribution of COVID-19 vaccines. Partnering…
Headline
The Department of Health and Human Services has agreed to purchase 66 million doses of Moderna’s omicron-specific COVID-19 vaccine booster for use this fall if…
Blog
In June, we traveled to Fajardo, Puerto Rico to attend the annual convention for the territory’s College of Health Services Administrators, known as CASS.…
Headline
The Centers for Disease Control and Prevention last night endorsed the two-dose Novavax COVID-19 vaccine as a COVID-19 vaccine primary series for…